• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    HH&L Acquisition Co. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8/10/23 6:51:23 AM ET
    $HHLA
    Medical Specialities
    Health Care
    Get the next $HHLA alert in real time by email
    0001824185 false --12-31 00-0000000 0001824185 2023-08-09 2023-08-09 0001824185 HHLA:ClassOrdinarySharesParValue0.0001PerShareMember 2023-08-09 2023-08-09 0001824185 HHLA:RedeemableWarrantsEachWholeWarrantExercisableForOneClassAOrdinaryShareAtAnExercisePriceOf11.50PerShareMember 2023-08-09 2023-08-09 0001824185 HHLA:UnitsEachConsistingOfOneClassOrdinaryShareAndOnehalfOfOneRedeemableWarrantMember 2023-08-09 2023-08-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(D)

    OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): August 10, 2023 (August 9, 2023)

     

    HH&L Acquisition Co.
    (Exact name of registrant as specified in its charter)

     

    Cayman Islands   001-40006   N/A
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (I.R.S. Employer
    Identification No.)

     

    Suite 2001-2002, 20/F, York House

    The Landmark, 15 Queen’s Road Central

    Central, Hong Kong 00000

    (Address of principal executive offices, including zip code)

     

    (852) 3752 2870

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Class A ordinary shares, par value $0.0001 per share   HHLA   The New York Stock Exchange
    Redeemable warrants, each whole warrant exercisable for one Class A ordinary share, each at an exercise price of $11.50 per share   HHLA WS   The New York Stock Exchange
    Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant   HHLA.U   The New York Stock Exchange

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

      

     

      

     

     

    Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

     

    The information disclosed in Item 5.07 of this Current Report on Form 8-K is incorporated by reference into this Item 5.03 to the extent required herein.

     

    Item 5.07 Submission of Matters to a Vote of Security Holders

     

    On August 9, 2023, at the Extraordinary General Meeting of HH&L Acquisition Co. (the “Company”) held on May 9, 2023 (the “Extraordinary General Meeting”), holders of 14,784,962 of the Company’s ordinary shares, which represents approximately 89.17% of the ordinary shares outstanding and entitled to vote as of the record date of August 1, 2023, were represented in person or by proxy.

     

    At the Extraordinary General Meeting, the shareholders approved (1) a special resolution to amend Articles 51.7 and 51.8 of the Company’s second amended and restated memorandum and articles of association, as amended by a special resolution of the Company’s shareholders on February 7, 2023 and May 9, 2023 (the “Second MAA”) to extend the date (the “Termination Date”) by which the Company must (i) consummate a business combination, or (ii) cease its operations except for the purpose of winding up if it fails to complete such business combination and redeem or repurchase 100% of the Company’s the issued and outstanding public shares, from August 9, 2023, without the need for any further approval of the Company’s shareholders, by resolutions of the Board of the Company at least three days prior to the applicable Extended Date, up to six times, each by an additional month, for an aggregate of six additional months, until February 9, 2024, without requiring the Company make any deposit into the Trust Account (the “Extension Amendment Proposal”). A copy of the amendment to our Second MAA is attached to this Current Report on Form 8-K as Exhibit 3.1 and incorporated herein by reference.

     

    1. The Extension Amendment Proposal. The Extension Amendment Proposal was approved. The final voting tabulation for this proposal was as follows:

     

    FOR  AGAINST  ABSTAIN
    13,824,484  960,478  0

     

    In connection with the vote to approve the Extension Amendment Proposal, the holders of 2,025,832 Class A ordinary shares elected to redeem their shares, leaving 4,205,185 Class A ordinary shares remain outstanding. The Company expects that the redemption price will be approximately $10.55 per share. The Company intends to complete the redemption of Class A ordinary shares as soon as possible after the Extraordinary General Meeting.

     

     

     

     

    The proposal to adjourn the Extraordinary General Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there were insufficient votes to approve the Extension Amendment Proposal or if the Company determines that additional time is necessary to effectuate the Extension, was not presented at the Extraordinary General Meeting, as the Extension Amendment Proposal received a sufficient number of votes required for approval.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Description
         
    3.1   Amendment to Second Amended and Restated Memorandum and Articles of Association
         
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      HH&L ACQUISITION CO.
         
      By: /s/ Richard Qi Li
      Name: Richard Qi Li
      Title: Chief Executive Officer and Director
    Date: August 10, 2023    

     

     

     

    Get the next $HHLA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HHLA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HHLA
    SEC Filings

    See more
    • SEC Form 25-NSE filed by HH&L Acquisition Co.

      25-NSE - HH&L Acquisition Co. (0001824185) (Subject)

      2/23/24 10:50:57 AM ET
      $HHLA
      Medical Specialities
      Health Care
    • HH&L Acquisition Co. filed SEC Form 8-K: Other Events

      8-K - HH&L Acquisition Co. (0001824185) (Filer)

      2/7/24 11:57:39 AM ET
      $HHLA
      Medical Specialities
      Health Care
    • SEC Form PRE 14A filed by HH&L Acquisition Co.

      PRE 14A - HH&L Acquisition Co. (0001824185) (Filer)

      1/23/24 5:14:45 PM ET
      $HHLA
      Medical Specialities
      Health Care

    $HHLA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • DiaCarta Receives Accreditation by the College of American Pathologists (CAP)

      PLEASNTON, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- DiaCarta, Ltd. ("DiaCarta"), a novel molecular diagnostic test developer for cancer and infectious diseases, today announced that it has received accreditation by the College of American Pathologists (CAP) for its CLIA certified lab. This accreditation is awarded to facilities that meet the high standards of quality, accuracy, and consistency in laboratory services required by CAP and underscores DiaCarta's leadership and commitment to excellence. "This CAP Accreditation is a tremendous accomplishment that signifies DiaCarta's commitment to excellence and I am proud of our team's dedication in support this major milestone," said Zheng 

      5/9/23 5:51:25 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • DiaCarta Announces Five Abstracts Accepted for Presentation at AACR Annual Meeting 2023

      Abstracts demonstrating XNA technology's improvements to assay sensitivity across different technology platforms and support for use in companion diagnostics (CDx) assay developmentAdditional abstracts to further support XNA technology's potential for use in minimal residual disease (MRD) monitoring of residual cancer cells PLEASANTON, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- DiaCarta, Ltd. ("DiaCarta"), a precision molecular diagnostics company, today announced that it will present five data posters at the American Association of Cancer Research (AACR) Annual Meeting 2023, which convenes in Orlando, Florida from April 14-19, 2023. The presentations will focus on how XNA can be used to

      4/16/23 2:00:00 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • DiaCarta Receives U.S. FDA Emergency Use Authorization for its Monkeypox Test Kit

      PLEASANTON, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- DiaCarta, Ltd. ("DiaCarta"), a precision molecular diagnostics company, today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for its QuantiVirusTM MPXV test, which is a PCR test for the qualitative detection of DNA from monkeypox virus (MPXV) in lesion swabs collected from individuals suspected of monkeypox infection. The test is designed for use by authorized laboratories on the most popular qPCR instruments, including the Thermo Fisher (ABI) QuantStudio5, Thermo Fisher (ABI) 7500 Fast Dx, Bio-Rad CFX384, and Roche LightCycler 480 II Systems. QuantiVirusTM MPXV test targets two di

      1/12/23 8:30:00 AM ET
      $HHLA
      Medical Specialities
      Health Care

    $HHLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Highbridge Capital Management Llc sold $2,687,500 worth of Class A Ordinary Shares (250,000 units at $10.75) (SEC Form 4)

      4 - HH&L Acquisition Co. (0001824185) (Issuer)

      1/12/24 4:15:16 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • SEC Form 3: New insider Highbridge Capital Management Llc claimed ownership of 500,000 units of Class A Ordinary Shares

      3 - HH&L Acquisition Co. (0001824185) (Issuer)

      8/15/23 4:30:21 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • SEC Form 4 filed by HH&L Investment Co.

      4 - HH&L Acquisition Co. (0001824185) (Issuer)

      5/19/21 11:16:35 AM ET
      $HHLA
      Medical Specialities
      Health Care

    $HHLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by HH&L Acquisition Co.

      SC 13G - HH&L Acquisition Co. (0001824185) (Subject)

      2/14/24 5:09:41 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by HH&L Acquisition Co.

      SC 13G - HH&L Acquisition Co. (0001824185) (Subject)

      2/13/24 8:00:58 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by HH&L Acquisition Co. (Amendment)

      SC 13G/A - HH&L Acquisition Co. (0001824185) (Subject)

      2/12/24 4:26:19 PM ET
      $HHLA
      Medical Specialities
      Health Care